| Year |
Citation |
Score |
| 2007 |
Lankes HA, Zanghi CN, Santos K, Capella C, Duke CM, Dewhurst S. In vivo gene delivery and expression by bacteriophage lambda vectors. Journal of Applied Microbiology. 102: 1337-49. PMID 17448169 DOI: 10.1111/J.1365-2672.2006.03182.X |
0.39 |
|
| 2007 |
Malboeuf CM, Simon DA, Lee YE, Lankes HA, Dewhurst S, Frelinger JG, Rose RC. Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo. Vaccine. 25: 3270-6. PMID 17293010 DOI: 10.1016/J.Vaccine.2007.01.067 |
0.532 |
|
| 2005 |
Zanghi CN, Lankes HA, Bradel-Tretheway B, Wegman J, Dewhurst S. A simple method for displaying recalcitrant proteins on the surface of bacteriophage lambda. Nucleic Acids Research. 33: e160. PMID 16224099 DOI: 10.1093/Nar/Gni158 |
0.533 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2016 |
Norquist B, Brady M, Harrell M, Walsh T, Lee M, Gulsuner S, Bernards S, Casadei S, Burger R, Davidson S, Mannel R, DiSilvestro P, Lankes H, Ramirez N, King M, et al. Mutations in homologous recombination genes and response to treatment in GOG 218: An NRG Oncology study Gynecologic Oncology. 141: 2. DOI: 10.1016/j.ygyno.2016.04.033 |
0.246 |
|
| 2019 |
Krill L, Deng W, Eskander R, Mutch D, Zweizig S, Hoang B, Ioffe O, Randall L, Lankes H, Miller DS, Birrer M. Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology. PMID 31843273 DOI: 10.1016/j.ygyno.2019.12.003 |
0.224 |
|
| 2017 |
Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes FJ, Mannel RS, Glaser G, Bailey C, Rubin SC, ... ... Lankes HA, et al. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29191972 DOI: 10.1158/1078-0432.Ccr-17-1327 |
0.205 |
|
| 2019 |
O'Cearbhaill RE, Deng W, Chen LM, Lucci JA, Behbakht K, Spirtos NM, Muller CY, Benigno BB, Powell MA, Berry E, Tewari KS, Hanjani P, Lankes HA, Aghajanian C, Sabbatini PJ. A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study. Gynecologic Oncology. PMID 31653510 DOI: 10.1016/j.ygyno.2019.09.015 |
0.164 |
|
| 2017 |
Thaker PH, Brady WE, Lankes HA, Odunsi K, Bradley WH, Moore KN, Muller CY, Anwer K, Schilder RJ, Alvarez RD, Fracasso PM. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. PMID 28802766 DOI: 10.1016/j.ygyno.2017.08.001 |
0.153 |
|
| 2017 |
Mayadev J, Brady WE, Lin YG, Da Silva DM, Lankes HA, Fracasso PM, Ghamande SA, Moore KN, Pham HQ, Wilkinson KJ, Kennedy VA, Aghajanian C, Koh W, Monk BJ, Schilder RJ. A phase I study of sequential ipilimumab in the definitive treatment of node positive cervical cancer: GOG 9929. Journal of Clinical Oncology. 35: 5526-5526. DOI: 10.1200/JCO.2017.35.15_suppl.5526 |
0.152 |
|
| 2020 |
Da Silva DM, Enserro DM, Mayadev J, Skeate JG, Matsuo K, Pham HQ, Lankes HA, Moxley KM, Ghamande S, Lin YG, Schilder RJ, Birrer MJ, Kast WM. Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32816895 DOI: 10.1158/1078-0432.Ccr-20-0776 |
0.144 |
|
| 2016 |
Sabbatini P, Chen L, Lucci JA, Behbakht K, Spirtos NM, Muller C, Benigno BB, Powell MA, Berry E, Tewari KS, Hanjani P, Deng W, Lankes HA, Aghajanian C. A phase II randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian (EOC), fallopian tube, or peritoneal cancer who are in second or third complete remission. Journal of Clinical Oncology. 34: 5517-5517. DOI: 10.1200/jco.2016.34.15_suppl.5517 |
0.143 |
|
| 2011 |
Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, Coleman RL, Miller BE, Rose PG, Lankes HA. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecologic Oncology. 121: 303-8. PMID 21329967 DOI: 10.1016/j.ygyno.2011.01.030 |
0.142 |
|
| 2016 |
Monk BJ, Facciabene A, Brady WE, Aghajanian C, Fracasso PM, Walker J, Lankes HA, Manjarrez KL, Danet-Desnoyers G, Bell-McGuinn KM, McCourt CK, Malykhin A, Hershberg RM, Coukos G. Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemo-immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27702821 DOI: 10.1158/1078-0432.CCR-16-1453 |
0.141 |
|
| 2023 |
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C. A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283. Gynecologic Oncology. 176: 16-24. PMID 37418832 DOI: 10.1016/j.ygyno.2023.06.021 |
0.139 |
|
| 2007 |
Hurd TC, Sait S, Kohga S, Winston J, Martinick M, Saxena R, Lankes H, Markus G, Harvey S, Gibbs JF. Plasminogen activator system localization in 60 cases of ductal carcinoma in situ Annals of Surgical Oncology. 14: 3117-3124. PMID 17701256 DOI: 10.1245/s10434-007-9529-y |
0.135 |
|
| 2012 |
Dellinger T, Eskander R, Ali S, Lankes H, Randall L, Ramirez N, Monk B, Walker J, Eisenhauer E, Hoang B. Expression patterns of the Wnt pathway inhibitors Dickkopf3 (Dkk3) and secreted frizzled-related proteins (SFRP) 1 and 4 in endometrial endometrioid adenocarcinoma: A Gynecologic Oncology Group study Gynecologic Oncology. 125: S141. DOI: 10.1016/j.ygyno.2011.12.346 |
0.134 |
|
| 2015 |
Eskander RN, Ali S, Dellinger T, Lankes HA, Randall LM, Ramirez NC, Monk BJ, Walker JL, Eisenhauer E, Hoang BH. Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 26397159 DOI: 10.1097/IGC.0000000000000563 |
0.13 |
|
| 2021 |
Leslie KK, Filiaci VL, Mallen AR, Thiel KW, Devor EJ, Moxley K, Richardson D, Mutch D, Secord AA, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Casablanca Y, ... ... Lankes H, et al. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecologic Oncology. PMID 33541735 DOI: 10.1016/j.ygyno.2021.01.025 |
0.129 |
|
| 2012 |
Gold MA, Brady WE, Lankes HA, Rose PG, Kelley JL, De Geest K, Crispens MA, Resnick KE, Howell SB. A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology. 125: 635-9. PMID 22446624 DOI: 10.1016/J.Ygyno.2012.03.023 |
0.129 |
|
| 2017 |
Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher E, et al. A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28327944 DOI: 10.1093/annonc/mdx049 |
0.126 |
|
| 2013 |
Monk BJ, Brady WE, Lankes HA, Facciabene A, Manjarrez K, Hershberg RM, Fracasso PM, Bell-McGuinn KM, Walker JL, McCourt CK, Aghajanian C, Coukos G. VTX-2337, a TLR8 agonist, plus chemotherapy in recurrent ovarian cancer: Preclinical and phase I data by the Gynecologic Oncology Group. Journal of Clinical Oncology. 31: 3077-3077. DOI: 10.1200/jco.2013.31.15_suppl.3077 |
0.124 |
|
| 2020 |
Santin AD, Deng W, Frumovitz M, Buza N, Bellone S, Huh W, Khleif S, Lankes HA, Ratner ES, O'Cearbhaill RE, Jazaeri AA, Birrer M. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecologic Oncology. PMID 31924334 DOI: 10.1016/j.ygyno.2019.12.034 |
0.121 |
|
| 2016 |
Thaker PH, Salani R, Brady WE, Lankes HA, Cohn DE, Mutch DG, Mannel RS, Bell-McGuinn KM, DiSilvestro PA, Jelovac D, Carter JS, Duan W, Resnick KE, Dizon DS, Aghajanian C, et al. A Phase I Trial of Paclitaxel, Cisplatin and Veliparib in the Treatment of Persistent or Recurrent Carcinoma of the Cervix: An NRG Oncology Study (NCT#01281852). Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 27998970 DOI: 10.1093/annonc/mdw635 |
0.12 |
|
| 2018 |
Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O'Malley DM, Stuckey A, Gao J, Dao F, Soslow RA, Lankes HA, Moore K, et al. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecologic Oncology. PMID 29804638 DOI: 10.1016/j.ygyno.2018.05.018 |
0.118 |
|
| 2017 |
Jandial DA, Brady WE, Howell SB, Lankes HA, Schilder RJ, Beumer JH, Christner SM, Strychor S, Powell MA, Hagemann AR, Moore KN, Walker JL, DiSilvestro PA, Duska LR, Fracasso PM, et al. A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. 145: 236-242. PMID 28341300 DOI: 10.1016/J.Ygyno.2017.03.013 |
0.116 |
|
| 2017 |
Grabosch S, Tseng G, Edwards RP, Lankes HA, Moore K, Odunsi K, Vlad A, Ma T, Strange M, Brozick J, Lugade A, Omilian A, Bshara W, Stuckey AR, Walker JL, et al. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology. PMID 28483269 DOI: 10.1016/J.Ygyno.2017.04.008 |
0.113 |
|
| 2012 |
Garcia AA, Sill MW, Lankes HA, Godwin AK, Mannel RS, Armstrong DK, Carolla RL, Liepman MK, Spirtos NM, Fischer EG, Leslie KK. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecologic Oncology. 124: 569-74. PMID 22037316 DOI: 10.1016/J.Ygyno.2011.10.022 |
0.105 |
|
| 2015 |
Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Yi Q, Burger RA, Chan JK, Davidson SA, Mannel RS, DiSilvestro PA, Lankes HA, et al. Inherited Mutations in Women With Ovarian Carcinoma. Jama Oncology. 1-9. PMID 26720728 DOI: 10.1001/Jamaoncol.2015.5495 |
0.104 |
|
| 2019 |
Mayadev J, Zamarin D, Deng W, Lankes H, O'Cearbhaill R, Aghajanian CA, Schilder R. Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 31871115 DOI: 10.1136/Ijgc-2019-001012 |
0.103 |
|
| 2019 |
Brooks RA, Tritchler DS, Darcy KM, Lankes HA, Salani R, Sperduto P, Guntupalli S, DiSilvestro P, Kesterson J, Olawaiye AB, Moxley K, Waggoner S, Santin A, Rader JS, Kizer NT, et al. GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. Gynecologic Oncology. PMID 30827726 DOI: 10.1016/J.Ygyno.2019.02.028 |
0.102 |
|
| 2011 |
Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 69-75. PMID 21098323 DOI: 10.1200/Jco.2009.26.7856 |
0.102 |
|
| 2020 |
Zamarin D, Burger RA, Sill MW, Powell DJ, Lankes HA, Feldman MD, Zivanovic O, Gunderson C, Ko E, Mathews C, Sharma S, Hagemann AR, Khleif S, Aghajanian C. Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902059. PMID 32275468 DOI: 10.1200/Jco.19.02059 |
0.101 |
|
| 2017 |
Monk B, Brady M, Aghajanian C, Lankes H, Rizack T, Leach J, Fowler J, Higgins R, Hanjani P, Morgan M. A phase II, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: A Gynecologic Oncology Group partners study Gynecologic Oncology. 145: 220-221. DOI: 10.1016/j.ygyno.2017.03.507 |
0.101 |
|
| 2017 |
Devor EJ, Miecznikowski J, Schickling BM, Gonzalez-Bosquet J, Lankes HA, Thaker P, Argenta PA, Pearl ML, Zweizig SL, Mannel RS, Brown A, Ramirez NC, Ioffe OB, Park KJ, Creasman WT, et al. Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. PMID 28969912 DOI: 10.1016/J.Ygyno.2017.09.025 |
0.1 |
|
| 2017 |
Rader JS, Sill MW, Beumer JH, Lankes HA, Benbrook DM, Garcia F, Trimble C, Tate Thigpen J, Lieberman R, Zuna RE, Leath CA, Spirtos NM, Byron J, Thaker PH, Lele S, et al. A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. PMID 28285845 DOI: 10.1016/J.Ygyno.2017.02.040 |
0.098 |
|
| 2012 |
Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, Mannel RS, Pathak HB, Hu W, Alpaugh RK, Sood AK, Godwin AK. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology. 127: 70-4. PMID 22710075 DOI: 10.1016/j.ygyno.2012.06.009 |
0.096 |
|
| 2016 |
Winder AD, Maniar KP, Wei JJ, Liu D, Scholtens DM, Lurain JR, Schink JC, Buttin BM, Filiaci VL, Lankes HA, Ramirez NC, Park K, Singh M, Lieberman RW, Mannel RS, et al. Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. Cancer. PMID 27926776 DOI: 10.1002/cncr.30477 |
0.095 |
|
| 2019 |
Huang GS, Merritt MA, Hutson A, Strickler HD, Einstein M, Brouwer-Visser J, Ramirez NC, Lankes HA, El-Bahrawy M, Xue X, Yu H, Mannel RS, O'Malley DM, Mutch DG, Disilvestro P, et al. Sex hormone, insulin, and insulin-like growth factor signaling in recurrence of high stage endometrial cancer: Results from the NRG Oncology/Gynecologic Oncology Group 210 trial. Journal of Clinical Oncology. 37: 5509-5509. DOI: 10.1200/Jco.2019.37.15_Suppl.5509 |
0.095 |
|
| 2012 |
Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecologic Oncology. 127: 538-43. PMID 22922531 DOI: 10.1016/J.Ygyno.2012.08.020 |
0.094 |
|
| 2013 |
Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. The Lancet. Oncology. 14: 134-40. PMID 23261356 DOI: 10.1016/S1470-2045(12)70572-7 |
0.094 |
|
| 2014 |
Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology. 135: 38-43. PMID 25019571 DOI: 10.1016/J.Ygyno.2014.07.083 |
0.094 |
|
| 2015 |
Mutch D, Powell M, Schmidt A, Broaddus R, Ramirez N, Tritchler D, Ali S, Lankes H, O'Malley D, Goodfellow P. Clinicopathologic features associated with defective DNA mismatch repair (MMR): A GOG 0210 cohort study of 1041 endometrioid endometrial cancer cases Gynecologic Oncology. 137: 20-21. DOI: 10.1016/J.Ygyno.2015.01.047 |
0.093 |
|
| 2014 |
Huh WK, Brady WE, Moore KN, Lankes HA, Monk BJ, Aghajanian C, Dizon DS, Armstrong DK, Thaker PH, Fracasso PM. A phase 2 study of live-attenuated listeria monocytogenes cancer immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265). Journal of Clinical Oncology. 32: TPS5617-TPS5617. DOI: 10.1200/jco.2014.32.15_suppl.tps5617 |
0.093 |
|
| 2017 |
von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, Hurria A, Mannel RS, Rizack T, Landrum LM, Rose PG, Salani R, Bradley WH, Rutherford TJ, Higgins RV, et al. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. Gynecologic Oncology. PMID 28089376 DOI: 10.1016/j.ygyno.2016.11.033 |
0.092 |
|
| 2016 |
Burger RA, Deng W, Makker V, Lankes HA, Aghajanian C, Gray HJ, Wade JL, Waggoner SE, Levine DA. PHASE II evaluation of dalantercept for persistent or recurrent epithelial ovarian and related cancers: An NRG oncology study. Journal of Clinical Oncology. 34: e17050-e17050. DOI: 10.1200/jco.2016.34.15_suppl.e17050 |
0.091 |
|
| 2018 |
Santin A, Deng W, Frumovitz MM, Huh WK, Khleif S, Lankes HA, Ratner E, O'Cearbhaill R, Jazaeri AA, Birrer M. A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer. Journal of Clinical Oncology. 36: 5536-5536. DOI: 10.1200/JCO.2018.36.15_SUPPL.5536 |
0.09 |
|
| 2014 |
Von Gruenigen V, Huang H, Tew W, Hurria A, Lankes H, DiSilvestro P, Mannel R, Beumer J, Heugel A, Herzog T. 3Geriatric assessment and tolerance to chemotherapy in elderly women with ovarian, primary peritoneal or fallopian tube cancer: A Gynecologic Oncology Group study Gynecologic Oncology. 134: 439. DOI: 10.1016/j.ygyno.2014.07.080 |
0.089 |
|
| 2009 |
Lankes HA, Fought AJ, Evens AM, Weisenburger DD, Chiu BC. Vaccination history and risk of non-Hodgkin lymphoma: a population-based, case-control study. Cancer Causes & Control : Ccc. 20: 517-23. PMID 19011978 DOI: 10.1007/s10552-008-9259-x |
0.088 |
|
| 2016 |
McMeekin DS, Tritchler DL, Cohn DE, Mutch DG, Lankes HA, Geller MA, Powell MA, Backes FJ, Landrum LM, Zaino R, Broaddus RD, Ramirez N, Gao F, Ali S, Darcy KM, et al. Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27325856 DOI: 10.1200/Jco.2016.67.8722 |
0.086 |
|
| 2015 |
Tewari K, Sill M, Monk B, Penson R, Lankes H, Leitao M, Ramondetta L, Van Le L, Richardson D, Landrum L, DiSilvestro P, Behbakht K, Ueland F, Michael H, Birrer M. Impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer: An NRG Oncology/Gynecologic Oncology Group study Gynecologic Oncology. 137: 12. DOI: 10.1016/J.Ygyno.2015.01.026 |
0.084 |
|
| 2015 |
Bender D, Sill MW, Lankes HA, Reyes HD, Darus CJ, Delmore JE, Rotmensch J, Gray HJ, Mannel RS, Schilder JM, Hunter MI, McCourt CK, Samuelson MI, Leslie KK. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. 138: 507-12. PMID 26186911 DOI: 10.1016/J.Ygyno.2015.04.018 |
0.083 |
|
| 2015 |
Bender D, Sill MW, Lankes HA, Reyes HD, Darus CJ, Delmore JE, Rotmensch J, Gray HJ, Mannel RS, Schilder JM, Hunter MI, McCourt CK, Samuelson MI, Leslie KK. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study Gynecologic Oncology. DOI: 10.1016/j.ygyno.2015.07.018 |
0.083 |
|
| 2012 |
Carter RL, Kang L, Darcy KM, Kauderer J, Liao SY, Rodgers WH, Walker JL, Lankes HA, Dunn ST, Stanbridge EJ. A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group study. Cancer Causes & Control : Ccc. 23: 2013-21. PMID 23073789 DOI: 10.1007/S10552-012-0081-0 |
0.081 |
|
| 2015 |
Aghajanian C, Filiaci VL, Dizon DS, Carlson J, Powell MA, Secord AA, Tewari KS, Bender D, O'Malley DM, Stuckey A, Rotmensch J, Levine DA, Lankes HA, Moore KN. A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. Journal of Clinical Oncology. 33: 5500-5500. DOI: 10.1200/jco.2015.33.15_suppl.5500 |
0.08 |
|
| 2016 |
McCourt CK, Deng W, Dizon DS, Lankes HA, Birrer MJ, Lomme MM, Powell MA, Kendrick JE, Saltzman JN, Warshal D, Tenney ME, Kushner DM, Aghajanian C. A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. PMID 28029447 DOI: 10.1016/j.ygyno.2016.10.026 |
0.079 |
|
| 2012 |
Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecologic Oncology. 127: 345-50. PMID 22885469 DOI: 10.1016/J.Ygyno.2012.07.127 |
0.077 |
|
| 2017 |
Hyman DM, Sill MW, Lankes HA, Piekarz R, Shahin MS, Ridgway MR, Backes F, Tenney ME, Mathews CA, Hoffman JS, Aghajanian C, Hensley ML. A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. Gynecologic Oncology. 144: 96-100. PMID 28094040 DOI: 10.1016/J.Ygyno.2016.10.036 |
0.075 |
|
| 2020 |
Alvarez Secord A, Bell Burdett K, Owzar K, Tritchler D, Sibley AB, Liu Y, Starr MD, Brady JC, Lankes HA, Hurwitz HI, Mannel RS, Tewari KS, O'Malley DM, Gray H, Bakkum-Gamez JN, et al. Predictive blood-based biomarkers in epithelial ovarian cancer patients treated with carboplatin and paclitaxel with or without bevacizumab: Results from GOG-0218. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31919136 DOI: 10.1158/1078-0432.Ccr-19-0226 |
0.075 |
|
| 2013 |
Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecologic Oncology. 129: 86-91. PMID 23321064 DOI: 10.1016/J.Ygyno.2013.01.006 |
0.074 |
|
| 2015 |
Thaker PH, Brady WE, Lankes HA, Cohn DE, Aghajanian C, Mutch DG, Mannel RS, Bell-McGuinn KM, DiSilvestro P, Jelovac D, Carter JS, Salani R. A limited access phase I trial of paclitaxel, cisplatin and ABT-888 in the treatment of advanced, persistent, or recurrent carcinoma of the cervix: An NRG/GOG study. Journal of Clinical Oncology. 33: 5600-5600. DOI: 10.1200/jco.2015.33.15_suppl.5600 |
0.074 |
|
| 2022 |
Casablanca Y, Wang G, Lankes HA, Tian C, Bateman NW, Miller CR, Chappell NP, Havrilesky LJ, Wallace AH, Ramirez NC, Miller DS, Oliver J, Mitchell D, Litzi T, Blanton BE, et al. Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: An NRG Oncology/Gynecologic Oncology Group Study. Cancers. 14. PMID 36077609 DOI: 10.3390/cancers14174070 |
0.073 |
|
| 2015 |
Zighelboim I, Ali S, Lankes HA, Backes F, Moore K, Mutch D, Robison K, Behbakht K, Waggoner S, Ghebre RG, Pearl M, Ramirez NC, Goodfellow P. Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. 138: 614-9. PMID 26144601 DOI: 10.1016/J.Ygyno.2015.06.038 |
0.072 |
|
| 2021 |
Duska LR, Filiaci VL, Walker JL, Holman LL, Hill EK, Moore RG, Ring KL, Pearl ML, Muller CY, Kushnir CL, Lankes HA, Samuelson MI, Carrick KS, Rajan A, Rodgers WH, et al. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33766814 DOI: 10.1158/1078-0432.CCR-20-4618 |
0.07 |
|
| 2007 |
Khan S, Lankes HA, Patil D, Bryk M, Nayar R, Hou N, Krontiras H, Rademaker A. Serial ductal lavage for biomarker assessment in a phase 2 prevention study with tamoxifen Journal of Clinical Oncology. 25: 1509-1509. DOI: 10.1200/jco.2007.25.18_suppl.1509 |
0.069 |
|
| 2019 |
Mayadev JS, Enserro D, Lin YG, Da Silva DM, Lankes HA, Aghajanian C, Ghamande S, Moore KN, Kennedy VA, Fracasso PM, Schilder RJ. Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer. Jama Oncology. PMID 31774464 DOI: 10.1001/jamaoncol.2019.3857 |
0.067 |
|
| 2017 |
Richardson DL, Sill MW, Coleman RL, Sood AK, Pearl ML, Kehoe SM, Carney ME, Hanjani P, Van Le L, Zhou XC, Alvarez Secord A, Gray HJ, Landrum LM, Lankes HA, Hu W, et al. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. Jama Oncology. PMID 29242937 DOI: 10.1001/Jamaoncol.2017.4218 |
0.065 |
|
| 2015 |
Rocconi RP, Lankes HA, Brady WE, Goodfellow PJ, Ramirez NC, Alvarez RD, Creasman W, Fernández JR. The role of racial genetic admixture with endometrial cancer outcomes: An NRG oncology/gynecologic oncology group study. Gynecologic Oncology. PMID 26603970 DOI: 10.1016/J.Ygyno.2015.11.018 |
0.064 |
|
| 2020 |
Tewari KS, Sill MW, Monk BJ, Penson RT, Moore DH, Lankes HA, Ramondetta LM, Landrum LM, Randall LM, Oaknin A, Leitao MM, Eisenhauer EL, DiSilvestro P, Van Le L, Pearl ML, et al. . Molecular Cancer Therapeutics. PMID 32847980 DOI: 10.1158/1535-7163.Mct-20-0276 |
0.064 |
|
| 2016 |
Secord AA, Tritchler D, Liu Y, Starr MD, Brady JC, Lankes HA, Hurwitz H, Mannel RS, Tewari KS, O'Malley DM, Gray HJ, Bakkum-Gamez JN, Fujiwara K, Boente M, Deng W, et al. Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218. Journal of Clinical Oncology. 34: 5521-5521. DOI: 10.1200/jco.2016.34.15_suppl.5521 |
0.063 |
|
| 2013 |
Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. Corrigendum to “A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study” [Gynecol Oncol 127 (2012) 538–543] Gynecologic Oncology. 130: 252-253. DOI: 10.1016/J.Ygyno.2013.04.007 |
0.062 |
|
| 2017 |
Moore KN, Tritchler D, Kaufman KM, Lankes H, Quinn MCJ, Van Le L, Berchuck A, Backes FJ, Tewari KS, Lee RB, Kesterson JP, Wenham RM, Armstrong DK, Krivak TC, et al. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. PMID 28935272 DOI: 10.1016/j.ygyno.2017.08.024 |
0.057 |
|
| 2021 |
Merritt MA, Strickler HD, Hutson AD, Einstein MH, Rohan TE, Xue X, Sherman ME, Brinton LA, Yu H, Miller DS, Ramirez NC, Lankes HA, Birrer MJ, Huang GS, Gunter MJ. Sex Hormone, Insulin and Insulin-like Growth Factor in Recurrence of High Stage Endometrial Cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 33622671 DOI: 10.1158/1055-9965.EPI-20-1613 |
0.056 |
|
| 2018 |
Levine D, Dizon D, Carlson J, Filiaci V, Powell M, Secord A, Tewari K, Bender D, O'Malley D, Stuckey A, Moore K, Dewdney S, Gao J, Dao F, Soslow R, ... Lankes H, et al. Predictive biomarkers of endometrial cancer response: Results from NRG Oncology/Gynecologic Oncology Group study 86P Gynecologic Oncology. 149: 12-13. DOI: 10.1016/J.YGYNO.2018.04.034 |
0.054 |
|
| 2008 |
Patil DB, Lankes HA, Nayar R, Masood S, Bryk M, Hou N, Rademaker A, Khan SA. Reproducibility of ductal lavage cytology and cellularity over a six month interval in high risk women. Breast Cancer Research and Treatment. 112: 327-33. PMID 18097749 DOI: 10.1007/s10549-007-9861-8 |
0.052 |
|
| 2020 |
Santin AD, Filiaci V, Bellone S, Ratner ES, Mathews CA, Cantuaria G, Gunderson CC, Rutledge T, Buttin BM, Lankes HA, Frumovitz M, Khleif SN, Huh WK, Birrer MJ. Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008). Gynecologic Oncology Reports. 31: 100532. PMID 31934607 DOI: 10.1016/j.gore.2019.100532 |
0.052 |
|
| 2013 |
Rocconi R, Fernandez J, Brady W, Darcy K, Goodfellow P, Lankes H, Tritchler D, Ramirez N, Creasman W, Alvarez R. The role of racial genetic admixture with endometrial cancer outcomes: A Gynecologic Oncology Group study Gynecologic Oncology. 130: e168-e169. DOI: 10.1016/J.Ygyno.2013.04.466 |
0.052 |
|
| 2019 |
Makhlouf H, Watson MA, Lankes HA, Weil C, Dickler M, Birrer M, Moskaluk C, Ramirez NC, Okby N, Alonsozana E, Barnes M, Goldman EB, Enos R, Lubensky I. Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical Trials. American Journal of Clinical Pathology. PMID 31613330 DOI: 10.1093/ajcp/aqz141 |
0.051 |
|
| 2017 |
Cosgrove CM, Tritchler DL, Cohn DE, Mutch DG, Rush CM, Lankes HA, Creasman WT, Miller DS, Ramirez NC, Geller MA, Powell MA, Backes FJ, Landrum LM, Timmers C, Suarez AA, et al. An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecologic Oncology. PMID 29132872 DOI: 10.1016/J.Ygyno.2017.10.037 |
0.051 |
|
| 2015 |
Billingsley C, Cohn D, Mutch D, Broaddus R, Ramirez N, Lankes H, Ali S, Backes F, Landrum L, Goodfellow P. Clinical implications for MSI, MLH1 methylation analysis and IHC in Lynch screening for endometrial cancer patients: An analysis of 940 endometrioid endometrial cancer cases from the GOG 0210 study Gynecologic Oncology. 137: 4-5. DOI: 10.1016/J.Ygyno.2015.01.008 |
0.05 |
|
| 2016 |
Swisher EM, Harrell MI, Norquist BM, Walsh T, Brady M, Lee M, Hershberg R, Kalli KR, Lankes H, Konnick EQ, Pritchard CC, Monk BJ, Chan JK, Burger R, Kaufmann SH, et al. Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma. Jama Oncology. PMID 26847329 DOI: 10.1001/Jamaoncol.2015.6053 |
0.05 |
|
| 2020 |
Santin AD, Filiaci V, Bellone S, O'Cearbhaill R, Ratner ES, Mathews CA, Cantuaria G, Gunderson CC, Rutledge T, Buttin BM, Lankes HA, Birrer MJ. Corrigendum to "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)" [Gynecol. Oncol. Rep. 31 (2020) 100532]. Gynecologic Oncology Reports. 33: 100590. PMID 32885014 DOI: 10.1016/j.gore.2020.100590 |
0.049 |
|
| 2015 |
Scalici J, Finan MA, Black J, Harmon MD, Nicolson W, Lankes HA, Brady WE, Rocconi RP. Minority participation in Gynecologic Oncology Group (GOG) Studies. Gynecologic Oncology. 138: 441-4. PMID 26013697 DOI: 10.1016/j.ygyno.2015.05.014 |
0.044 |
|
| 2017 |
Jeske YW, Ali S, Byron SA, Gao F, Mannel RS, Ghebre RG, DiSilvestro PA, Lele SB, Pearl ML, Schmidt AP, Lankes HA, Ramirez NC, Rasty G, Powell M, Goodfellow PJ, et al. FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. PMID 28314589 DOI: 10.1016/J.Ygyno.2017.02.031 |
0.044 |
|
| 2023 |
Osann K, Wenzel L, McKinney C, Wagner L, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Birrer M. Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors. Gynecologic Oncology. 171: 151-158. PMID 36905875 DOI: 10.1016/j.ygyno.2023.02.015 |
0.042 |
|
| 2009 |
Khan SA, Lankes HA, Patil DB, Bryk M, Hou N, Ivancic D, Nayar R, Masood S, Rademaker A. Ductal lavage is an inefficient method of biomarker measurement in high-risk women. Cancer Prevention Research (Philadelphia, Pa.). 2: 265-73. PMID 19223577 DOI: 10.1158/1940-6207.CAPR-08-0119 |
0.039 |
|
| 2022 |
Thiel KW, Devor EJ, Filiaci VL, Mutch D, Moxley K, Alvarez Secord A, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Aghajanian C, Samuelson MI, Lankes HA, Soslow RA, et al. Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2102506. PMID 35658479 DOI: 10.1200/JCO.21.02506 |
0.037 |
|
| 2021 |
Wenzel L, Osann K, McKinney C, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Mannel RS, Gray HJ, et al. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. Journal of the National Cancer Institute. PMID 33729494 DOI: 10.1093/jnci/djab034 |
0.036 |
|
| 2015 |
Goodfellow PJ, Billingsley CC, Lankes HA, Ali S, Cohn DE, Broaddus RJ, Ramirez N, Pritchard CC, Hampel H, Chassen AS, Simmons LV, Schmidt AP, Gao F, Brinton LA, Backes F, et al. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26552419 DOI: 10.1200/Jco.2015.63.9518 |
0.035 |
|
| 2017 |
Dockery L, Tritchler D, Krivak T, Kaufman K, Lankes H, Bae-Jump V, Berchuck A, Backes F, Rose P, Tewari K, Birrer M, Moore K, Bookman M. Genome-wide association study (GWAS) of single nucleotide polymorphisms (SNPs) and the risk of platinum and taxane toxicities: An analysis of GOG 172 and 182 Gynecologic Oncology. 145: 42-43. DOI: 10.1016/j.ygyno.2017.03.109 |
0.029 |
|
| 2015 |
Scalici J, Finan MA, Black J, Harmon MD, Nicolson W, Lankes HA, Brady WE, Rocconi RP. Minority participation in Gynecologic Oncology Group (GOG) Studies Gynecologic Oncology. DOI: 10.1016/j.ygyno.2015.05.014 |
0.026 |
|
| 2020 |
Mayadev J, Zamarin D, Deng W, Lankes H, O’Cearbhaill R, Aghajanian CA, Schilder R. Correction: . International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 30: 1084. PMID 32371424 DOI: 10.1136/ijgc-2019-001012corr1 |
0.017 |
|
| 2020 |
Lankes HA, Makhlouf H. Biospecimen Collection During the COVID-19 Pandemic. American Journal of Clinical Pathology. PMID 32974640 DOI: 10.1093/ajcp/aqaa171 |
0.01 |
|
| Hide low-probability matches. |